Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which progesterone form is best for IVF? new study aims to find out

NCT ID NCT07461909

Knowledge-focused Sponsor: Instituto Valenciano de Infertilidade de Lisboa Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two common forms of vaginal progesterone—soft capsules and pessaries—used during frozen embryo transfer. Researchers want to see which one women find more satisfying, convenient, and tolerable. About 400 women will use one of the two forms and report their experiences through online surveys. The study also checks hormone levels and pregnancy outcomes, but its main goal is to understand patient preferences.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
vaginal progesterone
What this could lead to
If successful, this could help doctors and patients choose the more convenient and tolerable progesterone formulation for frozen embryo transfer, potentially improving the experience.
What could go wrong
This is an observational study, not a randomized trial, so results may be influenced by patient or doctor preferences. It does not test a new treatment, only compares existing options.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of women aged 18 to 48 years undergoing frozen embryo transfer (FET) at IVI Lisboa. Eligible participants must have a BMI between 18.5 and \<30 kg/m², be scheduled for a single blastocyst-stage transfer, and be prescribed vaginal progesterone for luteal phase support, either soft capsules (400 mg every 12 hours) or pessaries (400 mg every 12 hours). Both artificial cycle (AC-FET) and natural proliferative phase (NPP-FET) protocols are included. The study population reflects real-world patients receiving routine clinical care.

Ages

18 to 48 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age: ≥18 and \<49 years old; * Body Mass Index (BMI) ≥18.5 Kg/m2 and \<30 Kg/m2; * Planned for single blastocyst stage transfer; * Has been prescribed two vaginal 200mg soft capsules or one 400mg pessary of progesterone, each 12hours before and after FET; * Either AC-FET or NPP-FET. Exclusion Criteria: * Women who have previously enrolled in this study; * Those unable to comprehend the investigational nature of the proposed study; * Rank of FET\>3; * Use of oral/injectable corticoids.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Artificial cycle are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

infertility disorder Patient Satisfaction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Artificial cycle Frozen embryo transfer (FET) Infertility Natural cycle

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Instituto Valenciano de Infertilidade (IVI Lisboa)

    RECRUITING

    Lisbon, 1800-282, Portugal

More trials for these conditions

Other studies related to the condition(s) this trial covers.